Retatrutide is an investigational triple agonist targeting GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide) and glucagon receptors, studied in the phase 2 obesity trial published in 2023 and now progressing through the Phase 3 TRIUMPH programme
Clinical studies have demonstrated that Mounjaro can lead to significant weight loss, with patients losing a substantial percentage of their body weight when combined with diet and exercise
Their combination of quality assurance and fast shipping places them in the upper tier of the research peptide market
Microglial glutamate uptake is coupled to glutathione synthesis and glutamate release
Sections were exposed to an imaging plate (Fuji Film, Tokyo, Japan) for 24 h and analysed using an FLA-7000 phosphorimaging system (Fuji Film)
Talley, Michael Horowitz, Michael A